2022 – Pfizer. (CIA Lim) Understanding Estrogen Receptor Signalling in CDK4/6i resistant Luminal Breast Cancers.
2022 – Ellipses. (CIA Lim) A pre-clinical study to determine the efficacy and mechanism of action of EP-0062, and develop a signature of response to EP-0062.
2022 – National Breast Cancer Foundation. (CIA Stirzaker) Novel epigenetic blood test for breast cancer detection and monitoring.
2021 – National Breast Cancer Foundation. (CIA Gallego) Accelerating next generation personalised medicine.
2020 – Cancer Council NSW. (CIA Achinger-Kawecka) Using epigenetic therapies to overcome endocrine resistance in breast cancer.
2020 – NHMRC Project Grant. (CIA Tilley) A combinatorial drug strategy to target lethal forms of breast cancer..
2020 – MRFF Genomics Grant. (CIA Lakhani) Whole Genome Sequencing in high-risk breast cancer patients.
2019 – Balnaves Foundation. A comprehensive approach to identifying and evaluating new therapies for patients with treatment-resistant breast cancer.
2019 – St Vincent’s Curran Foundation. Single Cell sequencing to evaluate the effects of endocrine therapy on the stroma.
2018 – St Vincent’s Clinic Foundation Grant. Reactivating p53 to combat CDK4/6 inhibitor resistance in ER positive Breast Cancer.
2018 – National Breast Cancer Foundation. Therapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer. (CIA Caldon).
2018 – National Breast Cancer Foundation. Targeting the p53 pathway in the age of CDK4/6 inhibitor resistant ER positive breast cancer. (CIA Portman).
2017 – NHMRC Development Grant. Development of a novel and highly selective CDK4/6 inhibitor for treating cancer (CIA S Wang).
2017 – NHMRC Project Grant. (CIA Tilley) Pushing AR toward better outcomes in breast and prostate cancers.
2017 – Movember & National Breast Cancer Foundation Collaborative Research Grant Initiative. Transforming endocrine therapy for breast and prostate cancer.
2017 – Cancer Council NSW. Progesterone as an anticancer therapy in early breast cancer.
2017 – Bayer Pharmaceuticals. Evaluating ODM201, an Selective AR degrader, in breast cancer.
2016 – NHMRC project grant. (CIA S Clark) Four dimensional epigenome remodelling: implications for endocrine resistance in breast cancer.
2016 – NHMRC project grant. (CIA W Tilley) The clinical significance of sex hormone crosstalk in estrogen receptor positive breast cancer.
2016 – NHMRC project grant. (CIA Y Haupt) Targeting the Oncoprotein MDMX as a Novel Treatment for Triple Negative Breast Cancer.
2016 – NHMRC project grant. (CIA S Tong) Development of vinorelbine as a tablet based therapy to cure ectopic pregnancies.
2016 – Thelma Greig Cancer Grant, St Vincent’s Clinic Foundation. Metabolic effects of exercise on breast cancer.
2016 – Novartis Australia. Evaluating MDM2 inhibitors in breast cancer.
2016 – Cancer Australia. A novel approach to overcome treatment-resistance in breast cancer.
2016 – National Breast Cancer Foundation. Identification of breast cancer subtype-specific tumour proteins in lymph nodes.
2015 – ANZ Breast Cancer Trialist Group. Targeting the p53 pathway in ER-positive breast cancer.
2014 – National Breast Cancer Foundation. Practitioner Fellowship. Sensitizing breast cancers to hormone receptor-directed therapies.
2014 – Ramaciotti Foundation. Evaluation of concurrent chemoendocrine therapy and predictive biomarkers for hormone receptor positive breast cancer.
2013 – Claudia Barr Adams Award, Dana-Farber Cancer Institute. The establishment of Patient Derived Breast Cancer Xenografts for the evaluation of novel therapies.
2011 – National Health & Medical Research Council. Overseas Biomedical Postdoctoral Fellowship. The identification of novel treatments for poor prognosis subgroups of breast cancer.
2013 – Pfizer Australia. Exploiting DNA repair deficits in non BRCA mutation associated breast cancer.
2012 – Dana-Farber Cancer Institute. Women’s Cancer Program. Unravelling the alterations in hormonal signalling during breast tumorigenesis.
2012 – Komen for the Cure. Sensitizing breast cancer to DNA damaging agents.
2011 – Breast Cancer Research Foundation. Combination of Bortezomib plus PARP inhibitor for Triple Negative Breast Cancer.
2010 – Dana-Farber Cancer Institute. Women’s Cancer Program. Defining epigenetic and estrogen receptor cistromic alterations in breast cancer.
2007 – Clinical Oncological Society of Australia. Characterization of human mammary stem and progenitor cells.
2006 – National Breast Cancer Foundation. Characterization of human mammary stem and progenitor cells.